Jody Charnow

A minimally invasive approach does not increase risk for atypical sites of kidney cancer recurrence, a recent study suggests.

In a study, men who underwent high-intensity focused ultrasound partial gland ablation for prostate cancer had excellent preservation of potency and continence.

In a retrospective study, addition of carboplatin to chemotherapy regimens improved survival in men with metastatic castration-resistant prostate cancer whose disease progressed on second-generation hormone therapy.

FDA has accepted a New Drug Application and granted Priority Review for darolutamide for the treatment of nonmetastatic castration-resistant prostate cancer.

FDA approved pembrolizumab, a PD-1 inhibitor, in combination with axitinib, a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma.

Radiation therapy administered after surgery for advanced upper tract urothelial carcinoma improves cancer-specific and distant metastasis-free survival, a study found.

Updated findings from a phase 3 study show significantly better 8-year progression-free survival with external beam radiation therapy added to androgen deprivation therapy (ADT) vs ADT alone.

In a study with a follow-up period of 18 years, men treated with any other modality but radical prostatectomy had higher prostate cancer death risks.

A population-based study found no effect of low-dose aspirin use within 1 year of diagnosis on prostate cancer death risk.